KISQALI FEMARA CO-PACK (COPACKAGED)
Details
- Status
- Prescription
- First Approved
- 2017-05-04
- Routes
- ORAL
- Dosage Forms
- TABLET
KISQALI FEMARA CO-PACK (COPACKAGED) Approval History
What KISQALI FEMARA CO-PACK (COPACKAGED) Treats
2 indicationsKISQALI FEMARA CO-PACK (COPACKAGED) is approved for 2 conditions since its original approval in 2017. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Early Breast Cancer
- Advanced Breast Cancer
Drugs Similar to KISQALI FEMARA CO-PACK (COPACKAGED)
FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
KISQALI FEMARA CO-PACK (COPACKAGED) FDA Label Details
ProIndications & Usage
FDA Label (PDF)Letrozole tablet is an aromatase inhibitor indicated for: Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer Extended adjuvant treatment of postmenopausal women with early breast cancer who have received prior standard adjuvant tamoxifen therapy First and second-line treatment of postmenopausal women with hormone receptor positive or unknown advanced breast cancer 1.1 Adjuvant Treatment of Early Breast Cancer Letrozole tablets are indicated for the adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer. 1.2 Exten...
KISQALI FEMARA CO-PACK (COPACKAGED) Patents & Exclusivity
Patents (18 active)
Exclusivity
Want competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.